Abstract
Due to its aggressive nature and high risk of postoperative recurrence, non-small cell lung cancer (NSCLC) remains a significant global health challenge, accounting for approximately 85% of all lung cancer cases. While modern drug therapies—including chemotherapy, targeted therapy, and immunotherapy—have improved clinical outcomes, the development of drug resistance remains the primary cause of treatment failure. Recent research has identified circular RNAs (circRNAs) as pivotal regulators in this process. These stable, non-coding RNAs modulate immune cell function, cytokines, autophagy, ferroptosis, and metabolism within the tumor microenvironment (TME). By functioning as microRNA (miRNA) sponges and interacting with specific signaling pathways, circRNAs directly contribute to therapeutic evasion. This review synthesizes the mechanisms underlying circRNA-mediated resistance and explores their potential as therapeutic targets to overcome drug resistance in NSCLC.
The Challenge of Acquired Resistance in NSCLC
Despite the introduction of advanced treatments like EGFR inhibitors and immune checkpoint blockers, NSCLC tumors frequently develop molecular workarounds. This acquired resistance is complex and multifaceted. CircRNAs, characterized by their unique closed-loop structure, offer a new lens through which to understand this phenomenon. Unlike linear RNAs, circRNAs are highly resistant to exonuclease degradation, making them stable biomarkers and functional drivers in the cellular landscape of resistant tumors.
Mechanisms of CircRNA-Mediated Resistance
Research indicates that circRNAs operate through several distinct functional pillars to promote cell survival under therapeutic stress.
Molecular Decoys and Cellular Logistics
The most prevalent mechanism is the "miRNA sponge" effect, where circRNAs act as competitive endogenous RNAs (ceRNAs). By binding to miRNAs, they prevent these small RNAs from silencing their target oncogenes. Beyond intracellular signaling, circRNAs facilitate intercellular communication via exosomes. Resistant cancer cells can package specific circRNAs into these extracellular vesicles and transmit them to sensitive neighboring cells, effectively spreading the resistant phenotype throughout the tumor.
Hijacking Signaling Pathways
CircRNAs manipulate critical signaling cascades, including the MAPK, Wnt, PI3K/AKT, and STAT3 pathways. For instance, in chemotherapy resistance, circ_SOX13 sponges miR-3194-3p, which normally suppresses the MAPRE1 gene; when overexpressed, this axis promotes cisplatin resistance. In the realm of immunotherapy, exosomal circUSP7 has been shown to induce CD8+ T-cell dysfunction, allowing tumors to evade the immune system.
Key Findings Across Treatment Modalities
Synthesis of recent experimental data reveals specific circRNA "drivers" for different therapies:
- Chemotherapy: circPVT1 and circ_0072088 are major contributors to Cisplatin resistance.
- Targeted Therapy: For third-generation EGFR inhibitors like Osimertinib, hsa_circ_0002130 drives resistance by sponging miR-498.
- Metabolic Reprogramming: Some circRNAs, such as circAKT3, influence resistance by curbing glycolysis or regulating autophagy-related proteins, altering how cells respond to toxic stress.
Limitations and Future Directions
While the role of circRNAs in NSCLC resistance is increasingly clear, several hurdles remain before these findings can be translated into clinical practice:
- Targeted Delivery: Developing nanoparticle-based systems to deliver circRNA "antidotes" (like siRNAs) specifically to lung tumors remains a bioengineering challenge.
- Network Complexity: A single circRNA often interacts with multiple miRNAs and proteins, leading to potential off-target effects when modulated.
- Clinical Validation: Most current evidence relies on pre-clinical models. Large-scale clinical trials are necessary to validate circRNAs as reliable predictive biomarkers.
In conclusion, circRNAs represent a frontier in oncology. Understanding their role as molecular switchboards not only clarifies the mechanisms of drug resistance but also opens new avenues for "resistance-reversing" combination therapies in NSCLC.
Summary updated